Nurix Therapeutics (NASDAQ:NRIX) Director Julia Gregory Sells 22,583 Shares of Company Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Director Julia Gregory sold 22,583 shares of the business’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the sale, the director owned 10,750 shares in the company, valued at $251,550. This represents a 67.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Nurix Therapeutics Trading Up 7.0%

Shares of Nurix Therapeutics stock opened at $23.67 on Thursday. The firm has a market cap of $2.46 billion, a PE ratio of 10.25 and a beta of 1.82. The stock has a 50 day moving average of $25.14 and a 200 day moving average of $21.06. Nurix Therapeutics, Inc. has a 12 month low of $9.18 and a 12 month high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 62.20%. The firm had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the subject of several analyst reports. Royal Bank Of Canada lowered their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating for the company in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Friday, July 17th. HC Wainwright upped their price target on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. BTIG Research reissued a “buy” rating and issued a $32.00 price objective on shares of Nurix Therapeutics in a research report on Friday, July 10th. Finally, Truist Financial reduced their price objective on shares of Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Nurix Therapeutics News Roundup

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Analysts remain constructive on Nurix’s outlook. Robert W. Baird raised its price target to $36 and maintained an “outperform” rating, while Needham reaffirmed a “buy” rating with a $34 target. Truist kept a “buy” rating despite trimming its target to $33. These targets imply substantial potential upside from recent trading levels. Nurix Therapeutics Q3 2026 Earnings
• Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 study of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst reiterated a “Strong Buy,” citing promising Phase 1/2 data, possible accelerated approval, partnerships and multiple development pathways. Nurix Strong Buy Analysis
• Positive Sentiment: RBC Capital Markets said Nurix’s enterprise value remains underappreciated, supporting the view that the stock’s valuation does not fully reflect its pipeline and commercial potential. RBC Capital Markets Valuation Commentary
• Neutral Sentiment: Nurix reported quarterly earnings well above consensus, largely reflecting unusually high revenue compared with estimates. However, the earnings reaction was pressured by rising operating expenses, highlighting continued investment needs for its clinical programs. Nurix Q3 Earnings and Operating Expenses
• Negative Sentiment: Director Julia P. Gregory sold 22,583 shares for approximately $528,000, reducing her direct holdings by 67.75%. Although insider sales can be made for personal or diversification reasons, the transaction may weigh modestly on sentiment. SEC Insider Trading Filing
• Negative Sentiment: Nurix faces execution and financial risks from its reliance on Roche for bexobrutideg, including cost burdens, reduced control and uncertain future returns. Nurix Roche Reliance Risk Analysis

Hedge Funds Weigh In On Nurix Therapeutics

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in Nurix Therapeutics by 95.4% during the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after buying an additional 620 shares during the period. Nykredit A S purchased a new position in shares of Nurix Therapeutics in the 2nd quarter valued at $32,000. Integrated Wealth Concepts LLC purchased a new position in shares of Nurix Therapeutics in the 2nd quarter valued at $33,000. KBC Group NV purchased a new position in shares of Nurix Therapeutics in the 1st quarter valued at $34,000. Finally, Avalon Trust Co bought a new position in shares of Nurix Therapeutics in the 2nd quarter worth $64,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.